Compare CCO & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CCO | WVE |
|---|---|---|
| Founded | 1995 | 2012 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 2005 | 2015 |
| Metric | CCO | WVE |
|---|---|---|
| Price | $2.40 | $5.87 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 16 |
| Target Price | $2.12 | ★ $29.81 |
| AVG Volume (30 Days) | ★ 7.3M | 3.5M |
| Earning Date | 05-07-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 110.81 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,604,140,000.00 | $3,704,000.00 |
| Revenue This Year | $5.35 | N/A |
| Revenue Next Year | $4.26 | $85.67 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 6.57 | ★ 149.43 |
| 52 Week Low | $1.00 | $5.02 |
| 52 Week High | $2.43 | $21.73 |
| Indicator | CCO | WVE |
|---|---|---|
| Relative Strength Index (RSI) | 49.35 | 39.51 |
| Support Level | $2.37 | $5.02 |
| Resistance Level | $2.41 | $7.65 |
| Average True Range (ATR) | 0.01 | 0.32 |
| MACD | -0.00 | 0.03 |
| Stochastic Oscillator | 25.00 | 37.34 |
Clear Channel Outdoor Holdings Inc is a provider of out-of-home advertising solutions. The company offers advertisers an opportunity to reach mass audiences across various high-traffic public spaces, by using its diverse portfolio of assets including roadside billboards, street furniture, and airport displays. Its reportable segments are; America (U.S. operations excluding airports), Airports (U.S. and Caribbean airport operations), and Other. A majority of its revenue is generated from the America segment which generates revenue from the sale of advertising on printed and digital out-of-home advertising displays such as bulletins, posters, street furniture, and others. Geographically, the company generates maximum revenue from the United States followed by Singapore.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.